|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM16573891X |
| 003 |
DE-627 |
| 005 |
20231223105340.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0553.xml
|
| 035 |
|
|
|a (DE-627)NLM16573891X
|
| 035 |
|
|
|a (NLM)17015038
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Howell, Michael D
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Mechanism of HBD-3 deficiency in atopic dermatitis
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.01.2007
|
| 500 |
|
|
|a Date Revised 02.04.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Extrinsic atopic dermatitis (EAD) and intrinsic atopic dermatitis (IAD) patients suffer from recurrent bacterial and viral infections. In this study, we demonstrate significantly decreased expression of human beta defensin (HBD)-3, a potent antimicrobial peptide (AMP), in lesional skin of both IAD (p<0.01) and EAD patients (p<0.01), as compared to psoriasis patients. Using primary keratinocytes from EAD and IAD patients, we determined that the deficiency in HBD-3 expression is an acquired rather than a constitutive defect. Furthermore, we demonstrate the down-regulatory effect of IL-4, IL-10, and IL-13 - which are over-expressed in the skin of AD patients - on HBD-3 expression in keratinocytes. Additionally, treatment of EAD skin explants with antibodies against IL-4, IL-10, and IL-13 augmented the expression of HBD-3. These studies suggest that neutralizing the Th2 cytokine milieu in AD skin may augment the innate immune response against bacterial and viral pathogens
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a DEFB103A protein, human
|2 NLM
|
| 650 |
|
7 |
|a Inflammation Mediators
|2 NLM
|
| 650 |
|
7 |
|a beta-Defensins
|2 NLM
|
| 700 |
1 |
|
|a Boguniewicz, Mark
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pastore, Saveria
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Novak, Natalija
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bieber, Thomas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Girolomoni, Giampiero
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Leung, Donald Y M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 121(2006), 3 vom: 15. Dez., Seite 332-8
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:121
|g year:2006
|g number:3
|g day:15
|g month:12
|g pages:332-8
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 121
|j 2006
|e 3
|b 15
|c 12
|h 332-8
|